Zelluna ASA (OSL:ZLNA)
Norway · Delayed Price · Currency is NOK 20.00
-0.50 (-2.44%)
Sep 14, 2026, 1:11 PM CET
Zelluna ASA Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
602.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 53.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 13.30M | 175.00K | 1.33% |
| Dec 31, 2021 | 13.13M | 704.38K | 5.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ArcticZymes Technologies ASA | 133.41M |
| Arctic Bioscience AS | 48.96M |
| Oncoinvent ASA | 24.31M |
| SoftOx Solutions AS | 16.27M |
| Aqua Bio Technology ASA | 5.67M |
| Nykode Therapeutics AS | 4.60M |
| Thor Medical ASA | 1.64M |
| Lytix Biopharma ASA | 377.00K |
Zelluna ASA News
- 24 days ago - Q2 2026 Zelluna ASA Earnings Presentation Transcript - GuruFocus
- 25 days ago - Zelluna Reports Q2 2026 Results, Advances First-in-Human TCR-NK Trial - Nasdaq
- 25 days ago - Zelluna ASA Earnings Call Transcript: Q2 2026 - Transcripts
- 25 days ago - Zelluna ASA Quarterly report: Q2 2026 - Filings
- 25 days ago - Zelluna ASA Slides: Q2 2026 - Filings
- 27 days ago - Zelluna Advances Phase 1 ZIMA-101 Trial Following Positive Safety Review From Independent Committee - Nasdaq
- 4 months ago - Zelluna ASA Earnings Call Transcript: Q1 2026 - Transcripts
- 4 months ago - Zelluna ASA Quarterly report: Q1 2026 - Filings